Infectious Disease

Infectious disease expert Amesh Adalja, MD, outlines the biggest vaccine policy shifts of 2025, including changes to COVID-19 and flu vaccine recommendations.

Nirsevimab lowered the risk of RSV-related illness by over 87% and hospitalizations by 98% in a new study.

Vaccination lowered influenza cases by about 33% to 42% in seasonal flu setups with 40% vaccine effectiveness, researchers reported.

Merck has launched phase 3 trials for MK-8527, a promising once-monthly HIV prevention pill, aiming to enhance PrEP options globally.

These new FDA-approved drugs include treatments for migraine, chronic spontaneous urticaria, RSV, and more.

The adult vaccine market is poised for explosive growth, with more than 100 product launches expected over the next 10 years. Are US clinicians ready?

Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.

New findings showcase the transformative impact of long-acting injectable therapies for effective HIV treatment and prevention.

A new study found racial disparities in COVID-19 antiviral prescribing, with clinic site, test type, and telehealth use explaining up to half the gap for Black and Latino patients.

Among recipients of high-dose CVXGA, relative vaccine effectiveness was 67.8% against symptomatic COVID infection at a median 7.3 months post-vaccination.